Abbott Laboratories vs. Sarepta Therapeutics,, Inc. Common Stock
ABT
Abbott Laboratories
$100.98 -0.31%
VS SRPTSarepta Therapeutics,, Inc. Common Stock
$18.50 -0.88%
Abbott Laboratories (ABT) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| ABT | SRPT | |
|---|---|---|
| Market Cap | $175.27 billion | $1.97 billion |
| Revenue (TTM) | $46.59 billion | $1.97 billion |
| Net Income (TTM) | $5.42 billion | $-136,725,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | SRPT | |
|---|---|---|
| P/E Ratio | 32.68 | — |
| Price / Book | 3.39 | 1.29 |
| Price / Sales | 3.76 | 1.00 |
SRPT leads on 2 of 2 valuation factors.
Profitability
| ABT | SRPT | |
|---|---|---|
| Net Margin | 11.65% | -6.93% |
| Return on Equity | 10.48% | -8.95% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | SRPT | |
|---|---|---|
| Dividend Yield | 2.50% | — |
| Payout Ratio | 81.55 | — |
ABT and SRPT split the dividend factors evenly.
Risk & Sentiment
| ABT | SRPT | |
|---|---|---|
| Short Interest | 0.57% | 9.38% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, SRPT overview, SRPT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.